Beta-1, Beta-2, Beta-3 adrenergic receptors (β1, β2, β3 adrenergic receptors (ADRB1, ADRB2, ADRB3))

The beta-adrenergic receptors (β1, β2, and β3) are members of the G protein-coupled receptor (GPCR) family, characterized by seven transmembrane helices[1][2][4][5]. These receptors mediate the effects of catecholamines (primarily epinephrine and norepinephrine) on target tissues by stimulating intracellular signaling pathways, most notably the Gs-protein–cAMP pathway. - **β1-adrenergic receptors** are predominantly expressed in the heart, where they increase heart rate and contractility, and in the kidney, stimulating renin release[3][4]. - **β2-adrenergic receptors** are found mainly in the lungs, vascular and uterine smooth muscle, as well as the liver and skeletal muscle, where they mediate bronchodilation, vasodilation, glycogenolysis, and muscle relaxation[5]. - **β3-adrenergic receptors** are primarily located in adipose tissue and the urinary bladder, regulating lipolysis and bladder relaxation[5][7]. Pharmacological targeting of these receptors has produced major classes of therapeutics including beta-blockers for cardiovascular conditions, β2 agonists for asthma and COPD, and β3 agonists for overactive bladder. This grouping as “β1, β2, β3 adrenergic receptors” gathers three distinct therapeutic targets into one entry. Each receptor has unique pharmacology, tissue distribution, and clinical implications. For structured data, individual entries for each subtype are recommended[2][3][5][7].

Other names

β1, β2, β3 adrenoceptorBeta-1, Beta-2, Beta-3 adrenoceptorAdrenergic receptor beta 1, 2, 3ADRB1, ADRB2, ADRB3

**Agonists:** Bind receptor → activate Gs protein → increase cAMP via adenylyl cyclase → downstream effects: increased heart rate and contractility (β1), smooth muscle relaxation (β2, β3), lipolysis (β1, β3), renin release (β1) - **Antagonists (beta-blockers):** Bind receptor and block endogenous catecholamines, decreasing heart rate, contractility, blood pressure (β1 predominant), and suppressing sympathetic overactivity